

Theravance Biopharma, Inc.  
Form 8-K/A  
August 28, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report: **August 10, 2015**  
(Date of earliest event reported)

**Theravance Biopharma, Inc.**

(Exact name of registrant as specified in its charter)

**Cayman Islands**  
(State or other jurisdiction  
of incorporation)

**001-36033**  
(Commission File  
Number)

**EIN 98-1226628**  
(IRS Employer  
Identification Number)

**PO Box 309, Ugland House, South Church**

**Street, George Town, Grand Cayman,**

**Cayman Islands**

(Address of principal executive offices)

**KY1-1104**  
(Zip Code)

Edgar Filing: Theravance Biopharma, Inc. - Form 8-K/A

**650-808-6000**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

*Explanatory Note*

*This amended Current Report on Form 8-K/A is filed solely to confirm that the press release attached to the Current Report on Form 8-K filed on August 10, 2015 (the Initial Report ) included information responsive to Item 2.02 of Form 8-K and to include the name and title of the officer that manually signed the Initial Report.*

**Item 2.02. Results of Operations and Financial Condition**

On August 10, 2015, Theravance Biopharma, Inc. issued a press release regarding its financial results for the quarter ended June 30, 2015. A copy of the press release was furnished as Exhibit 99.1 to the Initial Report.

The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K/A and the Initial Report, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Securities Exchange Act of 1934 ), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press Release dated August 10, 2015 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed August 10, 2015)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 28, 2015

**THERAVANCE BIOPHARMA, INC.**

By:

/s/ Renee D. Gala  
Renee D. Gala  
*Senior Vice President and  
Chief Financial Officer*